---
title: "PTC Therapeutics, Inc.  ( PTCT )  Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings - PTC Therapeutics  ( NASDAQ:PTCT ) "
description: "NEW YORK, July 03, 2024 ( GLOBE NEWSWIRE ) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of PTC Therapeutics, Inc. ( \"PTC\" or "
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/207923546.md"
published_at: "2024-07-03T20:41:10.000Z"
---

# PTC Therapeutics, Inc.  ( PTCT )  Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings - PTC Therapeutics  ( NASDAQ:PTCT ) 

> NEW YORK, July 03, 2024 ( GLOBE NEWSWIRE ) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of PTC Therapeutics, Inc. ( "PTC" or "the Company" ) PTCT. Investors who purchased PTC securities are encouraged to obtain additional ...

NEW YORK, July 03, 2024 ( GLOBE NEWSWIRE ) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of PTC Therapeutics, Inc. ( "PTC" or "the Company" ) PTCT. Investors who purchased PTC securities are encouraged to obtain additional ...

### Related Stocks

- [PTCT.US - PTC Therap](https://longbridge.com/en/quote/PTCT.US.md)
- [PTC.US - PTC](https://longbridge.com/en/quote/PTC.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 對 PTC 的平衡展望：Sephience 驅動的增長被杜氏肌營養不良的阻力所抵消，而未建模的 Vatiquinone 潛在上行則支持維持持有評級 | TD Cowen 的 Joseph Thome 對 PTC Therapeutics 維持持有評級，目標價為 75 美元。他提到 Sephience 的早期市場接受度強勁，以及 2026 年 7 億至 8 億美元的可信收入展望，但同時面臨杜 | [Link](https://longbridge.com/en/news/276406330.md) |
| PTC Therap｜10-K：2025 財年營收 17.31 億美元不及預期 |  | [Link](https://longbridge.com/en/news/276382414.md) |
| PTC 公司（PTC）通過與 SPG 的新 FlexPLM 合作如何塑造其智能 PLM 投資故事 | PTC 宣佈，SPG 公司選擇其 FlexPLM 解決方案以現代化產品生命週期運營，提升數據準確性和協作能力。這一勝利支持了 PTC 對智能產品生命週期的願景，並與其投資敍述相一致，預計到 2028 年收入將達到 33 億美元。儘管有積極的 | [Link](https://longbridge.com/en/news/276294946.md) |
| PTC Therap｜8-K：2025 財年 Q4 營收 1.65 億美元不及預期 |  | [Link](https://longbridge.com/en/news/276378877.md) |
| PTC Therapeutics 的盈利前景 | PTC Therapeutics（納斯達克代碼：PTCT）定於 2026 年 2 月 19 日發佈季度財報，分析師預計每股收益（EPS）為-0.33 美元。投資者對積極的指引公告抱有希望。該公司此前超出每股收益預期 1.34 美元，導致股價 | [Link](https://longbridge.com/en/news/276258138.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.